| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Regulation FD Disclosure
Registrant’s telephone number, including area code: (615) 733-4730 |
| 12 Nov 2026 | SCHEDULE 13G/A |
| 09 Nov 2026 | 10-Q |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
The second-half ramp we anticipated materialized as Harrow reported record third quarter revenue of $99.3 million, up 41% sequentially and 39% year over year. Branded products led the way, providing $83.5 million in revenue, up 62% year ... |
| 06 Nov 2026 | SCHEDULE 13G/A |
| 27 Oct 2026 | SCHEDULE 13G/A |
| 05 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +1 more
First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow’s Growing Ocular Surface Franchise |
| 04 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Effective September 4, 2026, Randall E. Pollard ceased serving as Chief Accounting Officer and principal accounting officer of Harrow, Inc. (the “Company”). |
| 21 Aug 2026 | 144 |
| 17 Aug 2026 |
Form 4: Shojaei Amir, CHIEF SCIENTIFIC OFFICER
Received 11,250 shares by exercise or conversion ($405K) · Sold 11,250 shares ($450K) |
| 10 Aug 2026 | 10-Q |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
The first half of 2026 was about driving demand and fine-tuning business rules; the second half is about converting growing demand into revenue and profits. The balance of this Letter to Stockholders describes why I believe we are set up... |
| 06 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
NASHVILLE, Tenn., August 6, 2026 – Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into a definitive agreement to acquire TYRVAYA® (varenicline so... |
| 31 Jul 2026 | SCHEDULE 13G/A |
| 22 Jun 2026 |
Form 4: Sternberg Perry J., Director
Granted 5,248 RSU |
| 22 Jun 2026 |
Form 4: Silvernail Lauren P, Director
Granted 5,248 RSU |
| 22 Jun 2026 |
Form 4: Graves Adrienne L, Director
Granted 5,248 RSU |
| 22 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 18, 2026, Harrow, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The number of shares of common stock entitled to vote at the Annual Meeting was 37,273,420. The number of shares of commo... |
| 03 Jun 2026 |
8-K: Regulation FD Disclosure
Attached as Exhibit 99.1 to this Current Report on Form 8-K is a corporate presentation of Harrow, Inc. (the “Company”), dated June 2026, which may be used from time to time by the Company’s management at investor conferences and in meet... |
| 19 May 2026 |
Form 4: Graves Adrienne L, Director
Bought 1,000 shares ($31.1K) |
Loading...